Scientists Discover Potential New Way to Treat Anxiety

Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural “endocannabinoids” without gastrointestinal side effects, Vanderbilt University scientists will report next week.
 
Endocannabinoids are natural signaling molecules that activate cannabinoid receptors in the brain, the same receptors turned on by the active ingredient in marijuana.
 
These receptors are also found in the gastrointestinal system and elsewhere in the body, and there is evidence that they play a role in wide range of physiological and pathological processes, in addition to modulating stress and anxiety.
 
If the “substrate-selective” COX-2 inhibitors developed at Vanderbilt also work in humans without side effects, they could represent a new approach to treating mood and anxiety disorders, the researchers conclude in a paper to be posted online Sunday in the journal Nature Neuroscience.
 
Clinical trials of some of these potential drugs could begin in the next several years, said Lawrence Marnett, Ph.D., director of the Vanderbilt Institute of Chemical Biology and the paper’s co-senior author with Sachin Patel, M.D., Ph.D.
 
The Vanderbilt scientists are pursuing other potential applications of activating endocannabinoids by substrate-selective COX-2 inhibition, including relieving pain, treating movement disorders, and possibly preventing colon cancer.
 
“The door is really wide open,” said Patel, assistant professor of Psychiatry and of Molecular Physiology & Biophysics. “We’ve just scratched the surface.”